The Sertindole Cohort Prospective (SCoP) study: Rationale, design and methodology

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 5, 2008, Pages 425-433

  Peuskens, Joseph ^a   Tanghøj, Per ^b   Mittoux, Aurélia ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b H LUNDBECK A S   (Denmark)

Author keywords

All cause mortality; Atypical antipsychotic; Randomized controlled trial; Risperidone; Safety; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EXTERNAL VALIDITY; FATALITY; FOLLOW UP; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; METHODOLOGY; MONOTHERAPY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SUICIDE ATTEMPT; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; ENDPOINT DETERMINATION; HUMANS; IMIDAZOLES; INDOLES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISPERIDONE; SCHIZOPHRENIA;

EID: 44249116196     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1594     Document Type: Review

References (29)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
2. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999; 60 (Suppl 23): 14-19.
3. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q 2000; 71: 373-384.
4. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998; 34: 61-69.
5. Hale A, Azorin JM, Kasper S, et al. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a Phase III trial. Int J Psych Clin Pract 2000; 4: 47-54.
6. Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a Phase III trial. Int J Psych Clin Pract 2000; 4: 55-62.
7. Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006; 21: 49-56.
8. Hyttel J, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect 1992; 89: 61-69.
9. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacologic characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101.
10. Sánchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuro-leptic compound. Drug Dev Res 1991; 22: 239-250.
11. Gleason S, Shannon H. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 1997; 129: 79-84.
12. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992; 10: 25-32.
13. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 792-791.
14. Didriksen M, Skarsfeldt T, Amt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 2007. Apr 4. Epub ahead of print.
15. Gallhofer B, Jaanson P, Mittoux A, Tangøj P, Lis S, Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: A randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007; 40: 275-286.
16. Eckardt L, Haverkamp W, Mertens M, et al. Drug-related torsade de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol and erythromycin. J Cardiovasc Pharmacol 1998; 32: 425-434.
17. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103: 2004-2013.
18. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsades de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002; 300: 64-71.
19. Nashelsky MB, Lawrence CH. Accuracy of cause of death determination without forensic autopsy examination. Am J Forensic Med Pathol 2003; 24: 313-319.
20. Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001; 15: 120-126.
21. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psych Clin Pract 2002; 6 (Suppl 1): 3-9.
22. Kittelson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics 1999; 55; 874-882.
23. User's Manual, Data Analysis Products Division, S+SEQTRIAL, MathSoft, Seattle, WA 2000.
24. Zanolla L, Zardini P. Selection of endpoints for heart failure clinical trials. Eur J Heart Fail 2003; 5: 717-723.
25. Pritt BS, Hardin NJ, Richmond JA, Shapiro SL. Death certification errors at an academic institution. Arch Pathol Lab Med 2005; 129: 1476-1479.
26. The Digitalis Investigations Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
27. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
28. Van Gelder IC, Wyse DG, Chandler ML, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006; 8: 935-942.
29. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl J Med 2006; 355: 2631-2639.